Dxome Co., Ltd.

Dxome Co., Ltd. is a molecular diagnostics company specializing in next-generation sequencing (NGS)–based solutions with a strong focus on liquid biopsy. By analyzing circulating tumor DNA (ctDNA) and hereditary mutations from a simple blood sample, Dxome enables treatment selection, therapy monitoring, and recurrence detection with exceptional sensitivity and accuracy. Its integrated approach—combining proprietary reagents, advanced sequencing panels, bioinformatics pipelines, and clinical reporting—has led to innovative products such as DxLiquid Pan100 and DxLiquid TMB500, which reduce the need for invasive tissue biopsies and support personalized medicine. Guided by its mission to deliver precise insights that improve patient outcomes, Dxome continues to invest in R&D, pursue global certifications including CLIA accreditation, and collaborate with hospitals and research institutions worldwide, positioning itself as a trusted leader in precision diagnostics for cancer and genetic diseases.